OpenNashEarnings

Medical Devices · NYSE: BSX

Boston Scientific earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 3 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Share loss in electrophysiology and Watchman, worsened by a cyberattack, leads Boston Scientific to call 2027 the trough while it leans on new launches and the pending Penumbra deal.

Two of Boston Scientific's biggest franchises, electrophysiology (EP) and Watchman, are now pulling the company down. EP is losing pulsed field ablation share to newer rival technologies, and Watchman's U.S. standalone procedures fell as physicians reassess the clinical evidence. An August cyber incident halted manufacturing and shipping for about eight business days. Interventional cardiology grew 19% and neuromodulation grew 13%, while urology, endoscopy and China pricing lagged.

Read the Q3 2026 summary →

Quarters

KPI history

Revenue$5.1B+1.4% y/yQ3 2026
Q4 2024: $4.6B (worked out from the annual figure)Q4 ’24$4.6BQ1 2025: $4.7BQ1 ’25$4.7BQ2 2025: $5.1BQ2 ’25$5.1BQ3 2025: $5.1BQ3 ’25$5.1BQ4 2025: $5.3B (worked out from the annual figure)Q4 ’25$5.3BQ1 2026: $5.2BQ1 ’26$5.2BQ2 2026: $5.4BQ2 ’26$5.4BQ3 2026: $5.1BQ3 ’26$5.1B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$4.6B *
Q1 2025$4.7B
Q2 2025$5.1B
Q3 2025$5.1B
Q4 2025$5.3B *
Q1 2026$5.2B
Q2 2026$5.4B
Q3 2026$5.1B
Diluted EPS (GAAP)$0.40−21.6% y/yQ3 2026
Q1 2025: $0.45Q1 ’25$0.45Q2 2025: $0.53Q2 ’25$0.53Q3 2025: $0.51Q3 ’25$0.51Q1 2026: $0.90Q1 ’26$0.90Q2 2026: $0.61Q2 ’26$0.61Q3 2026: $0.40Q3 ’26$0.40
Data
Q1 2025$0.45
Q2 2025$0.53
Q3 2025$0.51
Q1 2026$0.90
Q2 2026$0.61
Q3 2026$0.40

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin16.1%−4.6 pts y/yQ3 2026
Q4 2024: 14.8%Q4 ’2414.8%Q1 2025: 19.8%Q1 ’2519.8%Q2 2025: 16.2%Q2 ’2516.2%Q3 2025: 20.7%Q3 ’2520.7%Q4 2025: 15.6%Q4 ’2515.6%Q1 2026: 21.2%Q1 ’2621.2%Q2 2026: 21.6%Q2 ’2621.6%Q3 2026: 16.1%Q3 ’2616.1%
Data
Q4 202414.8%
Q1 202519.8%
Q2 202516.2%
Q3 202520.7%
Q4 202515.6%
Q1 202621.2%
Q2 202621.6%
Q3 202616.1%
Free cash flow$868.0M−25.3% y/yQ3 2026
Q4 2024: $1.2BQ4 ’24$1.2BQ1 2025: $354.0MQ1 ’25$354.0MQ2 2025: $1.1BQ2 ’25$1.1BQ3 2025: $1.2BQ3 ’25$1.2BQ4 2025: $1.0BQ4 ’25$1.0BQ1 2026: $171.0MQ1 ’26$171.0MQ2 2026: $1.3BQ2 ’26$1.3BQ3 2026: $868.0MQ3 ’26$868.0M
Data
Q4 2024$1.2B
Q1 2025$354.0M
Q2 2025$1.1B
Q3 2025$1.2B
Q4 2025$1.0B
Q1 2026$171.0M
Q2 2026$1.3B
Q3 2026$868.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$4.6Bd$4.7B$5.1B$5.1B$5.3Bd$5.2B$5.4B$5.1B
Gross margin67.9%68.8%67.7%69.9%69.6%69.5%70.7%66.7%
Operating income$675.0Md$921.0M$819.0M$1.0B$825.0Md$1.1B$1.2B$828.0M
Operating margin14.8%19.8%16.2%20.7%15.6%21.2%21.6%16.1%
Net income$562.0Md$672.0M$795.0M$755.0M$670.0Md$1.3B$905.0M$580.0M
Diluted EPS—$0.45$0.53$0.51—$0.90$0.61$0.40
Operating cash flow$1.5Bd$541.0M$1.3Bd$1.3Bd$1.4Bd$348.0M$1.5Bd$1.0Bd
Capital expenditure$277.0Md$187.0M$157.0Md$181.0Md$351.0Md$177.0M$195.0Md$180.0Md
Free cash flow$1.2B$354.0M$1.1B$1.2B$1.0B$171.0M$1.3B$868.0M
R&D expense$459.0Md$443.0M$526.0M$514.0M$569.0Md$516.0M$554.0M$520.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings